RxDoctor Payments Data

Royce Yount, MD

Cardiovascular Disease · New Orleans, LANPI 1881694594

Payments from drug & device makers

$9,599in general payments, 2019–2025

Across 68 payments — averaging $141.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Biotronik Inc.$702
  • Kestra Medical Technology Services, Inc.$556
  • Abbott$190
  • Abiomed$162
  • W. L. Gore & Associates, Inc.$143
  • plus $648 from 11 others

What the payments were for

  • Speaking & faculty fees$6,00063%
  • Food & beverage$3,58637%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,599 in reported general payments places this provider in the 70th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$103,347
Medicare patients
647
Services billed
1,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$364,731
Repatha SureclickEvolocumab160$99,068
XareltoRivaroxaban71$81,714
EntrestoSacubitril/Valsartan50$81,225
Praluent PenAlirocumab17$8,681
Metoprolol Succinate299$4,202
Valsartan93$3,004
Atorvastatin Calcium228$1,892
Torsemide82$1,673
Carvedilol224$1,470
Flecainide Acetate26$1,272
Losartan Potassium142$1,268
Amiodarone Hcl62$1,230
Ezetimibe107$1,180
Rosuvastatin Calcium75$1,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$65$81,22550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →